The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner - Yamamoto, Mizuki; Kiso, Maki; Sakai-Tagawa, Yuko; Iwatsuki-Horimoto, Kiyoko; Imai, Masaki; Takeda, Makoto; Kinoshita, Noriko; Ohmagari, Norio; Gohda, Jin; Semba, Kentaro; Matsuda, Zene; Kawaguchi, Yasushi; et al. (Viruses, 2020)
Keywords: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Animals; anticoagulants; Anticoagulants - pharmacology; Betacoronavirus - drug effects; Betacoronavirus - metabolism; blood; cell fusion; Cell Line; Chlorocebus aethiops; Communication; Coronavirus Infections - drug therapy; Coronavirus Infections - virology; COVID-19; COVID-19 infection; disseminated intravascular coagulation; etiological agents; fusion inhibitor; Gabexate - analogs & derivatives; Gabexate - pharmacology; Guanidines - pharmacology; HEK293 Cells; Humans; intravenous injection; lungs; median effective concentration; Middle East respiratory syndrome coronavirus; Pandemics; peptidyl-dipeptidase A; Peptidyl-Dipeptidase A - metabolism; pneumonia; Pneumonia, Viral - drug therapy; Pneumonia, Viral - virology; SARS-CoV-2; Serine Endopeptidases - metabolism; serine proteinases; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - antagonists & inhibitors; Spike Glycoprotein, Coronavirus - metabolism; TMPRSS2; Vero Cells; Virus Internalization - drug effects; TMPRSS2; SARS-CoV-2; fusion inhibitor